Procedura di valutazione comparativa per una posizione di Ricercatore a Tempo Determinato(RTD) nel Dipartirnento di Chimica e Tecnologie del Farmaco- Settore Concorsuale 03/Dl

Bando pubblicato sulla Gazzetta Uft'iciale IV serie speciale n. 4l del 2710512014

GIOVANNA POCE Cuniculum Vitae

Romat9t0620t4

Part I - General lnformation

Full Narne

!4e!ryIttPlace of Birth

Citizenshi

Permanent Address

Mobite Phone Number

E-mail

Langua

Part lI - Education

Type

University graduation

Licensure

Year lnstitutro-

Sapienza University of Rome,Faculty of Phanrracy.

Sapienza University of Rome,Faculty of Pharmacy.

Sapienza University of Rome,Faculty of Phamracy.

Notes

Abilitazione all'esercizio dellaprofessione di Farmacista.

Laurea in Chimica e TecnologiaFarmaceutiche. Tesi

rimentale dal titolo: "Sintesirelazioni struffura attività di

nuovi 1,5-diarilpirroli correlatiI RI\,'lr l ?"

Dottorato di Ricerca in ScienzeFarmaceutiche. Tesi dal titolo:"New pyrrole derivatives ofBM2l2: a new class ofantimycobacterial agents.Design, synthesis, biologicalevaluation and study of tlieirmode of action".

PhD

lt2t2004l

Part III - Appointments

Start End h.rstitution

tr/rolll F..*,rt I

F ro13l Fqzor,l

ITo/roro-ì Esrrp-;tl

W4rno1 fùzoorl

rrooDl FunA

FunqFa:r,A

FeAqfunozl

yro fu:rry]

Department of Phanr-iaceuticalChemistry and Technology, Sapienza

University of Rome.

Department of PlianlaceuticalChemistry and Technology, Sapienza

University of Rome.

Department of lmmunology and

Infectious Diseases, Harvard Schoolof Public Health.

Department of Chemistry, OxfordUniversity.

Department of PharmaceuticalChemistry and Technology, Sapienza

University of Rome.

Department of PharmaceuticalChernistry and Technology, Sapienza

University of Rome.

Department of PharmaceuticalChemistry and Technology, SapienzaUniversitv of Rome.

Depafirnent of iiran-naceuticalChemistry and Technology, SapienzaUniversitv of Rome.

Position

Assegnista di Ricerca, group of Prof.M. Biava.

Post-doc, group of Prof. M. Biava.

Visiting Scientist, group of Prof E. J.

Rubin.

Academic Visitor, group of Prof. S.

C. Davies.

Assegnista di Ricerca, group of Prof.G. C. Porretta.

Contratto per attività di ricerca, groupof Prof. M. Biava.

PhD student, tutor Prof. G. C.

Porretta.

Contratto per attività di ricerca, groupof Prof. M. Biava.

Part IV - Teaching experience

Year lnstitution

Part V -

Year

E-oo4-rllpresent I

Faculty of Pharmacy, Sapienza

University of Rome.

Faculty of Chemistry, Sapienza

University of Rome.

Lecture/Course

Teaching assistant in practical course of :

Analisi dei medicinali II.Teaching ll level master "Sostanze OrganicheNaturali".

Society memberberships

TitleMernber of the ltalian Cliernical Society (SCI).

Fart V - Funding lnformation Igrants as Pl-principal investigators,investigatorj

Year Title Program/role

Hit-to-lead development for a new classof antirnycobacterial agents.

Validazione del target molecolare delBM2l2, hii compound di una nuovaclasse di cornposti a potenl.c azioneantimicobatterica.

Nuovi derivati 1,5-difenil pirroliciad attività antitubercolare.

Derivati pirrolici del BM212: unanuova classe di composti ad attivitàantimicobatterica. Progettazione,sintesi, valutazione biologica e

studio del loro meccanismod'azione.

New pyrrole derivatives of BM 212:new class of antirnycobacterial

gents. Design, synthesis, biologicalluation and study of their mode

of action

Progettazione, sintesi, valutazionemicrobiologica e studio delnreccanismo di azione diderivati del BM2l2, potente agenteantitubercolare a struttura pirrolica.

Progettazione, sintesi, valutazionemicrobiologica, studi difarmacocinetica e di biodisponibilitàe del meccanismo di azione di nuoviderivati del BM2l2, agenteantitubercolare a strutfura pirrolica.

Sviluppo e caratterizzazione dinuovi farmaci antitubercolari conapprocci chimico-infonlatici,microbiologici, molecolari e

res Cantos Open Lab FoundationCSK, Madrid). PL

Progetti per Avvio alla Ricerca,Università Sapienza. Pl

Progetto di Ricerca diUniversità, UniversitàSapienza. I

Progetto di Ricerca diUniversità, UniversitàSapienza. I

lstituto Pasteur-FondazioneCenci-Bolosnetti. I

Progetto di Ricerca diUniversità, UniversitàSapienza. I

Progetto di Ricerca diUniversità, UniversitàSapienza. I

Pl-Project leader or l-

Grant value

r34000 €

2000 €

r2000 €

l 2000 €

60000 c

27600 €

1 1000 €

@w1l2ot4 |

@n-1

E-ou--]

lro-to-l

Progetto di Rìcerca diUniversità, UniversitàSapienza. I

26600 €

Fondazione CARIPLO. I 85610 €

Nuovi derivati del 8M212, agentintitubercolari a struttura pirrolica:loro progettazione, sintesi,valutazione microbiologica, studi difarmacocinetica e di biodisponibilitàe del meccanismo di azione.

lroo, -l

Eoos l

Wa? |

hooul

lroo5 I

Part VI - Rcsearch Activities

Keywords

uberculosis, Medicinalhemist

Tuberculosis, TargetIdentification.

Leishmania, MedicinalChemistrv.

Asymmetric Syntheses, LithiumAmides.

Stereospecific Conversion,Olefin, Cyclic Carbonate.

Nuovi agenti antitubercolari ;slruttura pirrolica, derivati del BM212: Ioro progettazione, sintesi,valutazione microbiologica, studi difarmacocinetica e di biodisponibilitàe del meccanismo di azione.

Progettazione, sintesi, valutazionernicrobioiogica e studio delmeccanismo di azione di nuoviagenti antitubercolari a strutturapirrolica, derivati del BM 212.

Sviluppo di nuovi farmacintitubercolari, valutazione della

loro attività antiniicobatterica eidentificazione del bersaglio

llulare.

Ricerca di Ateneo, UniversitàSapienza. I

Ricerca di Ateneo, UniversitàSapienza. I

ECoo€-l

FooG--l

Fioooa-l

Brief Description

lLead identification for a new class of anti,ry.obu.t".iul ug*À.-l

Design a,d sy,thesis of diaryrpyrrole acetic "ìt.Àìnoo*"awith ,itric oxide releasi,g propenies as analgesic/anti-

inflammatolry agents.

Asyrnmetric syntheses routes through d*blydiastesreoselective addition of enantiopure lithium amides toenantiopure N-enoyl oxazolidin-2-ones.

Developi,g small molecule f'luorophores as RNA mir,ics ogreen fl --;scent protein.

Developing microfluidic paper-based urulytiàl - d.ri..,(FPADs) for poinr-of-care TB diagnostics.

J

Design and synthesis of sm"all molecules ,.t,* ,g"*.tLeishmania donovani.

ne-pot conversions of olefins to cyclic carbonates andsecondary allylic and homoallylic aniines to cyclic carbamates.

Part Vtl - Summary of Scicntific Achievements

VIIA - Publications

Product type Data Base

Papers Iinternational]

Number

E-----l[----_-]

Number

-

-

6;------_-ll-' I

Start End

Books [scientific]

VIIB - Conference communications

Product type

ral presentations [asinvited speaker

ral tions

Posters

VUC - lmpact factor/citations

otal lmpact factor

Scopus Eoos---ltor4 -_lwq------,tw-l

96.24

In Dress

'otal Citations 339

Average Citations per Product t3.56

Hirsch (H) index

Nonnalized H index* 0,1 I

*H index divided by the academic seniority ltirre span tì'oru graduation)

Part IX - Sclected Publications/Confcrcncc comnrunications

List of the publications and conference courrnunications sclccted fbr the evalr-ration.

IXA - Publications:

1. Poce, C.; Bates, H. R.; Alfonso, S.; Cocozza, M.; Porretta, C.C.; Biava, M.; Ballel, L.; Rullas, J.;

Ortega, F.; De Logu, A.; Agus, A., La Rosa, V.; Pasca, M.R.; De Rossi, E.; Wae, B.; Franzblau, S.

G.; Manetti, F.; Botta, M.; Biava, M. lmproved BM2l2 Mrnpl3 tnhibitor Analogue Shows Efficacyin Acute Murine Modet of Tubercirlosis lnfection. Plos One2013, B, e56980.

I F : 3 .73 0. C itat ions: 4

2. La Rosa, V.; Poce, C.; Canseco, J.O.; Buroni, S.; Pasca, M. R.; Biava, M.; Raju, R.M.; Pon'etta,

C.C.; AIfonso, S.; Battilocchio, C.; Javid, B.; Solrentino, F.; ioerger, T. R.; Sacchettini, J. C.;

Manerri, F.; Botta, M.; De Logu, A.; Rubin, E. J.; De Rossi, E. MmpL3 is the Cellular Target of the

Antitubercular Pyrrole Derivative BMz12. Antinicrob. Agents Chentother.2012, 56,324-331.

lF : 4.565. Citations: 30

3. Biava, M.; Pon'etta, C. C.; Poce, C.; Battilocchio, C.; Alfonso, S.; De Logu, A.; Manetti, F.; Botta

M. Developing Pyrrole-Derived Artimycobacterial Agents: a Rational Lead Optimization Approach.

I ChetnMedChetn20ll.6,593-598.

1t

IF :2.835. Citations: 6

4. Davies, S. G.: Fletcher, A. M.; Kurosawa, W.; Lee, -l A.; Poce, G'; Roberts, P' M'; Thomson, J E'';

Wiiliarnsol, D. M. One-por Conversions of Oletjns to Cyciic Carbonates and Secondary Allylic and

llorr,oallylic An.rines to Cyclic Carbatrates. J Org Chent.,20rc, 75, 1145-1156.

lF :4.564. Citations: 2t)

5. Biava, M.; Porretta, C. C.; Poce, G.; Battiiocchio. C.; Alfor-iso, S.; De Logu, A', Saddi, N.; Manetti,

F.; Botta M. lclentification ol a Novel Pyrrole Derivative Endowed with Antimycobacterial Activity

and Protection lndex Comparable to that of the Current Antitubercular Drugs Streptomycin and

Rifampin. Bioorg. Med. Chen. 2010, lB, 8076-8084.

lF :2.903. Citations: l3

7. Davies,S.C.; FletchcrM.A.; llertrrann, C.J.; Poce,G.; Roberts,P.M.; Srnith,A'D.; Sweet,M J';

Thonsol, .l . I1. DoLrbly Diastereoselective Conjugate Acldition ol Enantiopure Lithium Amides to

Elanriopure N-Enoyl òxazoliclin-2-Oncs: a Mechanistic Probe. Tetahedron. Asyntnery2010, 21,

I 635-l 648.

lF:2.115. Citations: 9

8. Biava, M.; Porretta, C. C.; Poce, C.; De Logu, A., Meleddu, R.; De Rossi, E.; Manetti, F.; Botta M.

1,5-Diaryl-2-ethyl Pyrrole Derivatives as Antirnycobacterial Agents: Design, Syntiresis, and

Microbiological Evaluation. Eur. J. Med Chen. 21J09. 44, 4134-4138'

lF : 3.499. Citations: 27

g. Biava, M.;Poletta, C. C.; Poce, C.;De Logu, A.; Saddi, M.; Meleddu, R.; Manctti, F.;De Rossi, E.;

Botta, M. 1,5-Diphenyl Pyrrole Derivatives as Antirnycol'racierial Agents. Probing the lnfluetlce on

AnrimycobacterialActivity of Lipophylic Substituents at the Phenyl Rings. J. Med. Cltent-2008,51,

3644-3648.IF : 5.614. Citatior-rs: 28

10. Biava, M.; Pol'etta, C.C.; Poce, C.; Supino, S.; Cappelli, A.; Vomcro, S., Manetti, F.; Botta, M';

Sautebin, L.; Rossi, a.; Cheiarciini, C.; vivoii, E.; viakovec, F.; .,r.nzeiiorri, F.; Fatrignani, F';

A1zi11i, M. COX-2 inhibitors. 1,5-Diarytpyrrole-3-Acetic Esters with Enhanced Inhibitory Activity

Toward COX-2 and irnproved COX-2/COX-1 Selectivity. J. Med. Chent.2007, 50,5403-5411.

lF : 5.614. Citations: 22

11. Biava, M.; Porretta, C. C.; Poce, C.; Supino, S.; Deidda, D.; Pornpei, R.; Molicotti, P.; Manetti, F';

Botta, M. Antigycobacterial Agents. Novel Diarylpirrole Derivatives of BM2 l2 Endowed with

High Activity Toward Mycobacteriun tuberculosrs aud Low Cylotoxicity. J. Med. Chem.2006, 49,

49464952.lF : 5.6 14. Citations: 47

12. Biava, M., Ponetta, C. C.; Poce, C.; Deidcla, D.; Porr-rpei, R., Tafi, A.; Manetti, F' Antirnycobacterial

Cornpounds. Optirnization of the BM2l2 Structure, the Lead Cornpound for a New Pyrrole

Derivative Class. Bioorg. Med Chen 2005, 13' l22l-1230'lF : 2.903. Citations: 3 I

IXB - Oral corrmunications as ìr-ivited speaker:

l. Poce, C. Towarcls Tirbcrculosis TrcaLurent with Novel MmpL3 lnhibitors. Dipartimento

Dipartimento cli Scienze FarrraceuticÌre, Ur.riversità degli Studi di Perugia, l8 March 20 14. (Seminar)

2. Poce, C. BM2l2-Derived MrnpL3 lnhibitors Enabling New Possibilities for the Treattrent of TB.

Tuberculosis DrLrg Developrrerìt, Gordon Researcl.t Conference, Barga (LU),21-26 luly 20ir3.

(Keynote)

3. Poce, C. Hit-to-Lead Developrreut for a New Class of Anti-Mycobacterial Agents. Tres Cantos

Open Lab FoLrndation, Tres Cantos, l0 June 2013. (Serninar)

4. Poce, G.; Porretta, C.C; De Logu, A.; De Rossi, E.; RLrbin, E.J.; Ballel, L.; Botta, M., Biava, M. 1,5-

Diphenyl Pyrroles as New Antirnycobacterial Agents. Hit-to-lead Development and Target

Validation. COST Action Meeting CM080l, Siena, 29-3 I May 2012. (Oral presentation)

IXC - Oral cournunications:

l. Poce, G.; Alfonso, S.; Cocozza, M.; Botta, M.; Fernandez-Menendez, R.; Ballel, L.; Bates, R.H.;Franzblau, S.; Rubin, E. J.; De Logu, A.; De Rossi, E., Biava, M. Towards Tr-rberculosis Treatment

witl-r Next Ceneration 8M635 Ar-ralogs. NPCF8. Panra, 9-l I June 2014.

2. Alfonso, S.; Cocozza, M.; Poce, C.; Porretta, C.C.; Bates, R.H., Ballel, L.; RLrllas,.l .. Ortega, F.; De

Logu, A.; Agus, A.; Dc Rossi, E.; Wae, W.; Frartzblau, S.G.; Manetti, F.; Botta, M.; Biava, M.

Mrrpl3 Lrhibitors Enabling New Possibilitics t-ol TB Treatrnent. XXll National Meeting on

Medicinal Clreuristry, Ronte, I 0- ì 3 Septerrber 20 I 3.

3. Biava, M.; Porr-etta, G.C., Poce, G.; Alfcrnso, S.; Battilocchio, C.; De Logu, A.; Manetti, F'; Botta,

M. Identification of a New Chen-rical Series o1'Poterìt Antimycobacterial Compounds. XX National

Meeting on Mcdicinal CÌremistry, Abl- : Tertrle, l2- 16 Septernber 2010.

4. Biava, M., Porretta, C. C.; Poce, C.; Dc Logu, A.; Manctti, F.; Botta, M. New Pyrrole Derivatives ofBM 212: a New Class ol Antintycobacterial Agcnts. Design, Synthesis, Biological Evaluation and

Study of their Mode of Action. NPCF3, Barga (LU), l3-14 February 2009.

IXD - Posters:

l. Poce, G.; Biava, M., Ponetta, C.C.; Battilocchio, C., Alibnso,S.; Botta, M.; Javid, B.; Sorrentino,

F.; Ioerger, T.R.; Sacchettini, J.R.; Rubin, E. BM212 Targets Mrnpl3.Tuberculosis Drug

Development, Gordon Research Conference, Barga (LU),4-8 July 20 I l.

2. Biava, M.; Porretta, G.C.; Poce, C.; Alfonso, S.; Battilocchio, C.; De Logu, A.; Manetti, F.; Botta,

M. 8M579: a Novel Pyrrole Derivatives with lmproved Antirnycobacterial Activity. lV Meeting

NPCF, Santa Margherita diPula,6-7 May 2010.

Biava, M.; Porretta, C C.; Poce, C.; Battilocchio, C.; Alfonso, S'; De Logr"r, A., De Rossi, E';

Manetti, F.; Botta, M. New Pyrrole Derivatives of BM2Ì2: a New Class of Antimycobacterial

Agenrs. Design, Synthesis, Biological Evaluation and Study of Their Mode of Action. Cost ActionMeeting (CM080l-New Dlugs For Neglected Diseases), Certosa di Pontignano, Siena,28-29 May

20r0.

Poce, C.; Biava, M.; Polretta, C. C. Microwave Assisted Synthetic Pathways, a Rapid Approach to

Obtain Substituted Pyn'oles and lrridazoles as Antirnycobacterial and Anti-lnflalilnatory Agents.

Zing- Microwave and Flow Chernistry Conference. Antigua, 28-3 I Januarv 2009.

3.

4.

6.

1.

8.

5. Poce, C., Porretta, C. C.; Dc Logu, A.; De Rossi, E.; Maneui, F.; Botta, M.; Biava, M. BM212 andits Derivatives: Lead Optirrization of a New Class of Antirrycobacterial Agents. "Cost Action",Rauischholzhausen Castle, Gennany, l9-2 I March 2009.

Biava, M.; Porretta, C.C.; Battilocchio, C.; Poce, G.; De Logu, A., Manetti, F.; Botta, M. PyrroleDerivatìves of BM2 l2 as Novel Antimycobacterial Agents. Desigr-r, Synthesis, Biological Evaluationand Study of theirMode olAction. XXVIII Convegno Nazionale SIMGBM, della Società italiana dìMicrobiologia Cenerale e Biotecnologie Microbiche, Spoleto, ll-13 iune 2009.

Poce, G.; Porretta, C. C.; Borzi, F.; De LogLi, A.; De Rossi, E.; Mzrnetti, F.; Botta, M.; Biava, M.New Pyn'ole Derivatives of BM2l2: Lead Compound Optirnization Strategy. Tuberculosis drugdevelopment. Targets, tecluologies aud trials" Magdalen College, Oxford, United Kingdorn, 16-2 IAugust 2009.

Biava, M.; Porretta, C.C.; Poce, C.; De Logu, A.; Malecldu, R.; De Rossi, E.; Manetti, F.; Botta, M.Dcsign ancl Synthesis o1' I,5-Diaryl-2-Ethyl Pyn'ole Derivatives and their Evaluation asArrtimycobacteriai Agents. XIX National Mccting on Medicinal Chemistry Division of ltalianCherrical Society (SCI), Verona, 14-18 September' 2008.

9. Poce, G.; Porretta, G.C.; Borzi, F.; De Logu, A.; De Rossi, E.; Manetti, F.; Botta, M.; Biava, M.BM2l2 and New Derivatives as a New Class of Antimycobacterial Agents. First IRBM workshop onMedicinal & Organic Chemistry. Pomezia (RM),26 Septernber 2008.

l0.Biava, M.; Porretta, C.C.; Poce, C.; Deidda, D.; Pornpei, R.; Manetti, F.; Botta, M. Design, Synthesisand Screening of New Antitubercular Agents Derived frorn BM 212. Vl Laboratorio di MetodologieSintetiche in Chirnica Famaceutica. Siena, I I - I 6 February 2007 .

I i.Poce, C. Synthesis of New Pyrrole Derivatives of BM 212, a Potent Antirnycobacterial Compound.European School of Medicinal Chemistry (ESMEC), l-6 July 2007.

l2.Biava, M.; J)orretta, C.C;Poce, C.; De LogLr, A.; Manetti, F.; Botta, M. New 1,5-diphenyl PyrroleDerived lì-orn BM 212: a New class 01 Antin.ìycobacterial Agents. Tuberculosis Dlug Developlnent.Cordon Rescarch ConÈrer.rcc, Oxf'ord, 26-3 I August20tJ7.

l3.Biava, M.; Polrclt-a, C.C.; Poce, C.; Supino, C.; Derdcia, D.; Porlpei, R.; Manetti, F.; Botra, M.Synthesis of New Pyrrole Derivatives o1'BM2l2, a Potent Antimycobacterial Cornpound, XXIICongresso Nazior.rale della Società Chimica Italiana, Fircnze, l0-15 Septernber 2006.

l4.Biava. M.; Porretta, C C; Pocc. C.: Deidda. I).: Irtlmuei. R.: l'afi. A.: Manetti. F. Nuovi Derivati1,5-Difenilpirrolici Dcrivati del BM2l2 Atrivr conrc Agenti Autitubercolari. XVll National Meetingol Medicinal Chemistry Division ol ltalian Clrcmical Society (SCl), Pisa, 6- l0 Seprernber 2A04.

Part X - Othcr Scicntific Achio,cmcnts

XA-Peer reviewer for intemational -journals;

l. ACS Medicinal Cher.nistry Letters2. ChemMedCheur3. Expert Opinion on Therapeutic Targets4. Journal of Pharmacy and Pharrr-racology5. M olecu les

6. African Journal of Pharmacy and Pharmacology

XB-lnvitation for writrng perspeciives and book chapter:

1. Poce, C.; Porretta, C. C.; Biava, M. C-9 Alkenylidine Bridged Macrolides: WO2008061189. EnantaPhannaceuticals, Inc. Expert Opin. Ther. Pat. 2009, 19, 901-6.

2. Biava, M.; Poce, C. Ovcrcor.r-rrng Drug Resistarce ibr TLrberculosis in Overcoming Drug Resistancein Infectious Diseases. Future Science.

XC-Session Clrairrnarr

Session: Alternative Approaciies to Target lD and Drug Discovery. Tuberculosis Drug Development,Gordon-Kenan Researcl.r Sen-rinar, Barga (LU),20-2I July 2013.

XD-Collaboraiions:

l. Eric J. Rubin, Harvard University, Boston, US.

2. George W. Whitesides, Harvard University, Boston, US.

3. Lluis Baliell, Tres Cantos Medicines Developurent Campirs, GlaxoSrnithKline, Tres Cantos, Spain.4. Celia Gouldir-rg, Fort Collins, University olCalrfbrnia, lrvine, US.

5. Mary Jackson, Colorado State University. Forr Collins, US.

6. Chng Shu Sin, National Ur-riversity of Singapore, Singapore, Republic of Singapore.7. Claudia Crestini, Univcrsity of Tol Vergata, Ronie, ltaly.

Roma, 1910612014

Ciovanna Pocc

.....- .--r- [